From Acomplia (rimonabant) Trials results:
ACOMPLIA (TM) 20mg:
Key Findings from Completed Trials:
Robust data replicated in 3 large studies showing consistent results
- Significant reduction in waist circumference and weight
- Weight-independent improvement in several metabolic variables
- Achieved effacy at year 1, maintained at the end of year 2 with chronic therapy
- Decreased number of patients with metabolic syndrome
- Well tolerated
- Improved quality of life
http://en.sanofi-aventis.com/Images/20050210_cluzel_en_tcm24-2416.pdf
Rimonabant | Acomplia | Weight Loss | Quit Smoking | Reduce Risk Of Heart Disease
Rimonabant, discovered and developed by sanofi-aventis,
is thought to represent a new approach for the comprehensive
management of cardiovascular risk factors. The compound has
been studied to date in over 6,500 overweight and obese adults
for up to 2 years.
Despite therapeutic advances in recent decades, cardiovascular
disease remains the leading cause of mortality worldwide.
Current treatments generally target risk factors individually,
rather than providing a comprehensive management approach to
such cardiovascular risks as dyslipidemia, abdominal obesity
and insulin resistance, which comprise the metabolic syndrome.
As the first selective CB1 blocker, the effects of rimonabant
on lipid and glucose metabolism, insulin resistance and
reduced intra-abdominal adiposity, evidenced by a reduction in
waist circumference, have been studied. Abdominal obesity is
recognized as a significant risk factor in the development of
cardiovascular disease.
Rimonabant also has been studied by sanofi-aventis as an aid
to smoking cessation based on studies for up to one year in
over 6,500 smokers motivated to quit smoking.